RET and cancer: In dopamine neurons, GDNF mainly signals via RET receptor [122, 123], suggesting that RET inhibitors such as Selpercatinib [124] and Pralsetinib [125], currently used in cancer therapy, may carry potential to treat a subgroup of patients with schizophrenia.